Actavis agrees successful refinancing

– Albrecht to chair the Board

 Reykjavik, Iceland, 21 July 2010 ? Actavis Group, the international generic
pharmaceuticals company, today announced it has successfully agreed a debt
refinancing in collaboration with its lenders.

The refinancing gives Actavis a capital structure that positions the Company
strongly for the future and provides it with the flexibility to continue to
grow, especially in southern Europe, Japan, the Middle East & northern Africa,
and increase market penetration in current geographies. Another key priority
will be the entry into the segment of biological products (biosimilars), a
product group which requires a strong financial position due to the high
development cost. Combined with the potential for strong operational performance
and the recent appointment of Dr. Claudio Albrecht as CEO, the refinancing
transaction puts Actavis in a strong position to achieve its growth targets.

The refinancing has the full backing of Actavis“ management team and its key
stakeholders.  Dr. Claudio Albrecht will also chair the Board, which will be
further strengthened by the appointment of non-executive directors, some of whom
have extensive industry experience.

Dr. Claudio Albrecht, Chief Executive of Actavis said: „With the refinancing
successfully agreed on, the Group is now well placed for the future and can
continue to execute its growth strategy on a robust platform, providing
additional stability and opportunity for Actavis“ employees both in Iceland and
around the world.“

The refinancing is expected to complete after satisfaction of customary
conditions in the coming months.

      – ENDS –

Enquiries:

Financial Dynamics (London)              Actavis Group

Charles Armitstead / Hazel Stevenson         Hjördís Árnadóttir

Tel: +44 207 269 7176                        Tel: (+354) 535 2300 /
840 7476                                     E-mail: harnadottir@actavis.com

About Actavis Group
Actavis is one of the world“s leading generic pharmaceutical companies
specializing in the development, manufacture and sale of generic
pharmaceuticals.  The company has operations in 40 countries, with 10,000
employees. For further information on Actavis Group, please visit
www.actavis.com

Any statements contained in this press release that refer to Actavis“ estimated
or anticipated future results or future activities are forward-looking
statements which reflect the Company“s current analysis of existing trends,
information and plans. These forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to differ materially
depending on factors such as the availability of resources, the timing and
effect of regulatory actions, the success of new products, the strength of
competition, the success of research and development issues, unexpected contract
breaches or terminations, exposure to product liability and other lawsuits, the
effect of currency fluctuations and other factors.

[HUG#1433368]

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.

Source: Actavis via Thomson Reuters ONE